Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 223

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 223
---
 deficit(451,024)(568,779)Total stockholders' equity706,734 571,553 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$757,165 $615,886 

See notes to condensed consolidated financial statements.

5

KEROS THERAPEUTICS, INC. 

Condensed Consolidated Statements of Operations 

(In thousands, except share and per share data) 

(Unaudited)

THREE MONTHS ENDED JUNE 30,SIX MONTHS ENDED JUNE 30,2025202420252024REVENUE:Service and other revenue$18,168 $37 $34,059 $120 License revenue— — 195,355 — Total revenue18,168 37 229,414 120 OPERATING EXPENSES:Research and development(43,503)(40,515)(92,212)(78,773)General and administrative(14,482)(9,961)(24,979)(20,269)Total operating expenses(57,985)(50,476)(117,191)(99,042)INCOME (LOSS) FROM OPERATIONS(39,817)(50,439)112,223 (98,922)OTHER INCOME (EXPENSE), NETDividend income7,120 5,378 13,912 11,184 Other expense, net(221)(196)(559)(633)Total other income, net6,899 5,182 13,353 10,551 Income (loss) before income taxes(32,918)(45,257)125,576 (88,371)Income tax (provision) benefit2,222 — (7,821)— Net income (loss)$(30,696)$(45,257)$117,755 $(88,371)Net income (loss) attributable to common stockholders — basic and diluted (Note 8)$(30,696)$(45,257)$117,755 $(88,371)Weighted-average shares of common stock outstanding — basic40,612,90736,103,18740,586,27935,894,305Weighted-average shares of common stock outstanding — diluted40,612,90736,103,18741,153,75835,894,305Net income (loss) per share of common stock — basic$(0.76)$(1.25)$2.90